Dermatology Games

Treatment Options for Hidradenitis Suppurativa

Introduction

Hidradenitis suppurativa(HS) represents a chronic inflammatory dermatological condition manifesting with recurrent suppurative nodules, cutaneous abscesses, and subsequent development of subcutaneous fistulae with scar formation. The pathology significantly impacts psychosocial functioning due to purulent exudate and associated malodor.

The condition primarily affects apocrine-rich anatomical regions, notably the axillary, inguinal, perianal, perineal, and inframammary areas. HS exhibits significant comorbidity with metabolic syndrome, cardiovascular pathologies, inflammatory bowel disease, and axial spondyloarthropathy.

The etiopathogenesis remains incompletely elucidated, complicating therapeutic approaches. While mild cases respond to conservative management including lifestyle modification and antimicrobial therapy, moderate-to-severe disease presents significant therapeutic challenges due to refractory nature to conventional interventions.

Quality of life impact is substantial, manifesting through psychological morbidity, occupational impairment, intimate relationship dysfunction, chronic algesia, and substance use disorders. This emphasizes the necessity for expeditious diagnosis and implementation of efficacious therapeutic strategies.


1. Lifestyle & General Management

A. Lifestyle Modifications

B. General Management Strategies


2. Medical Treatment Options

A. Topical Treatments

B. Intralesional Therapy

C. Systemic Antibiotics

  1. Doxycycline: 50-100mg twice daily initially for 3 months.
  2. Combined therapy:
    • Clindamycin 300mg twice daily
    • Rifampicin 600mg daily
    • Duration: 12 weeks
  3. Triple therapy:
    • Moxifloxacin 400mg daily
    • Rifampicin 10mg/kg daily
    • Metronidazole 500mg thrice daily
    • Duration: up to 12 weeks

D. Hormonal Therapy

Hormonal therapy is often considered for female HS patients due to the potential role of androgens in HS development.

E. Biologic Therapy

  1. Adalimumab(FDA-approved):
    • Week 0: 160mg subcutaneous
    • Week 2: 80mg subcutaneous
    • Maintenance: 40mg weekly
  2. Secukinumab(FDA-approved):
    • Initial: 300mg weekly for 5 weeks
    • Maintenance: 300mg every 4 weeks
  3. Anakinra:
    • 100 mg daily for 12 weeks.
  4. Infliximab:
    • Initial: 5 mg/kg intravenously at weeks 0, 2, and 6.
    • Maintenance: every 6–8 weeks, depending on patient response and tolerance.

F. Other treatment options


3. Surgical Interventions


References

This website uses cookies.

This website uses cookies.

Exit mobile version